Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38590198)

  • 1. [First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient 
with EGFR Exon 20 Insertion Mutantion].
    Li Z; Wei T; Zeng D; Zhao L; Zhang J; Chen L
    Zhongguo Fei Ai Za Zhi; 2024 Mar; 27(3):241-244. PubMed ID: 38590198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.
    Han H; Zhang X; Liu X; Zhao J; Zhang J; Zhang J; Zhu H; Jiao S; Tang H
    Medicine (Baltimore); 2023 Dec; 102(52):e36667. PubMed ID: 38206746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Furmonertinib: First Approval.
    Deeks ED
    Drugs; 2021 Oct; 81(15):1775-1780. PubMed ID: 34528187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Sa H; Shi Y; Ding C; Ma K
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7729-7742. PubMed ID: 37004599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes.
    Chouaid C; Filleron T; Debieuvre D; Pérol M; Girard N; Dansin E; Lena H; Gervais R; Cousin S; Otto J; Schott R; Planchard D; Madroszyk A; Kaderbhai C; Dubray-Longeras P; Hiret S; Pichon E; Clément-Duchêne C; Chenuc G; Simon G; Bosquet L; QUantin X
    Target Oncol; 2021 Nov; 16(6):801-811. PubMed ID: 34661827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
    Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
    Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
    Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
    BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary Adenocarcinoma Patient with Complex Mutations on EGFR Benefits from Furmonertinib after Acquiring Gefitinib Resistance: A Case Report.
    Wu G; Chen Q; Lv D; Lin L; Huang J
    Recent Pat Anticancer Drug Discov; 2024; 19(2):247-252. PubMed ID: 38214361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.
    Ding Y; Dong H; Li Y; Liu L; Cai Y; Wang Y; Tian S; Dai C
    Medicine (Baltimore); 2022 Jul; 101(29):e29332. PubMed ID: 35866776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
    Shi Y; Chen G; Wang X; Liu Y; Wu L; Hao Y; Liu C; Zhu S; Zhang X; Li Y; Liu J; Cao L; Cheng Y; Zhao H; Zhang S; Zang A; Cui J; Feng J; Yang N; Liu F; Jiang Y; Gu C;
    Lancet Respir Med; 2022 Nov; 10(11):1019-1028. PubMed ID: 35662408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review.
    Burnett H; Emich H; Carroll C; Stapleton N; Mahadevia P; Li T
    PLoS One; 2021; 16(3):e0247620. PubMed ID: 33684140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report.
    Zhou T; Xiong Q; Hong C; Wang Q; Wang W; Xu C; Cai J;
    Medicine (Baltimore); 2022 Aug; 101(34):e30269. PubMed ID: 36042660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences.
    Chen L; Zhou Y; Gan C; Wang X; Liu Y; Dong C; He R; Yang J
    Cancer Invest; 2022 Aug; 40(7):590-603. PubMed ID: 35445633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
    van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
    Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.
    Zhao R; Li J; Guo L; Xiang C; Chen S; Zhao J; Shao J; Zhu L; Ye M; Qin G; Chu T; Han Y
    Target Oncol; 2024 Mar; 19(2):277-288. PubMed ID: 38416376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.
    Jiang W; Sha M; Chen C
    Am J Ther; 2023 Nov-Dec 01; 30(6):e570-e572. PubMed ID: 35482932
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report.
    Deng Y; Yang C; Liu W; Cai S; Guo X
    Anticancer Drugs; 2022 Apr; 33(4):406-412. PubMed ID: 35266890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].
    Yang X; Zhao J
    Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):337-350. PubMed ID: 35599009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
    Wu JY; Yu CJ; Shih JY
    Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.